DEFB112抗体—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P05644(DEFB112 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The DEFB112 antibody is designed to target human beta-defensin 112 (DEFB112), a small cationic peptide encoded by the DEFB112 gene. As a member of the β-defensin family, DEFB112 is primarily involved in innate immunity, exhibiting antimicrobial activity against bacteria, viruses, and fungi. It is expressed in epithelial tissues, including the respiratory tract, reproductive organs, and skin, where it contributes to mucosal defense and immune modulation. Structurally, DEFB112 contains six conserved cysteine residues forming three disulfide bonds, a hallmark of defensins, which stabilize its β-sheet-rich fold for pathogen membrane disruption.

Research highlights DEFB112's dual role in host defense and cellular signaling. Beyond direct microbicidal effects, it interacts with chemokine receptors (e.g., CCR6) to recruit immune cells, linking innate and adaptive immunity. Dysregulation of DEFB112 has been implicated in inflammatory diseases, infections, and cancers. For example, altered expression is observed in prostate and lung cancers, suggesting potential diagnostic or prognostic utility. The DEFB112 antibody serves as a critical tool for detecting protein localization, expression levels, and functional studies via techniques like Western blot, immunohistochemistry, and immunofluorescence. Its application aids in elucidating DEFB112's mechanisms in disease pathogenesis and therapeutic development, particularly in antimicrobial resistance and cancer immunotherapy.